The first clinical studies for a new type of immunotherapy for leukaemia are beginning at Bern’s Inselspital, Bern University Hospital. Antibodies discovered in the laboratory should inhibit the growth of tumour cells.
Leukaemia stem cells: they have the ability to renew themselves and are resistant to most current, existing cancer therapies (chemotherapy, radiation, targeted medications) . Because the cells are responsible for the development of blood cancer, they also regulate the course of disease. The faster they multiply, the faster the illness progresses.
Therefore, since 2009, the tumour immunology researchers PD Dr. sc. nat. Carsten Riether and Dr. Christian Schürz have been studying the characteristics of leukaemia stem cells at the Department of Clinical Research, along with the University Clinic for Medical Oncology at Inselspital, Bern University Hospital. In the “Journal of Experimental Medicine”, they could demonstrate that the interaction between the CD70 and CD27 cell molecules leads to higher growth.
Attacking leukaemia at its source
In order to heal acute leukaemia, the leukaemia stem cells must be eliminated. Accordingly, they play a central role in the treatment of the illness. The immunology researchers in Bern were able to develop an antibody in a lab that blocks the CD70/CD27 interaction in the tumour cells, which blocks the multiplication of healthy, haematopoietic stem cells, but does not limit them. In the recently published pre-clinical study, this led to the inhibited development of the illness and prolonged survival.
As a result, the renowned immunotherapy researcher Prof. Dr. med. Adrian Ochsenbein’s research group laid the foundation for a clinical study at Inselspital, Bern University Hospital. Beginning in January 2017, a pilot group of patients with acute leukaemia will have access to new, promising treatment methods for an illness that is otherwise often very difficult.
(Concerning the publication:) PD Dr. sc. nat. Carsten Riether, Tumor-Immunology Research Group, Department of Clinical Research, Tel. +41 31 632 87 95, email@example.com.
(Concerning the clinical study:) Prof. Dr. med. Adrian Ochsenbein, Director and Chief Physician, University Clinic for Medical Oncology, Inselspital, Bern University Hospital, Tel. +41 31 632 84 42, firstname.lastname@example.org.
Monika Kugemann | Universitätsspital Bern
Live probiotics can re-balance the gut microbiome and modify immune system response
20.11.2018 | Symprove
Purdue cancer identity technology makes it easier to find a tumor's 'address'
16.11.2018 | Purdue University
Max Planck researchers revel the nano-structure of molecular trains and the reason for smooth transport in cellular antennas.
Moving around, sensing the extracellular environment, and signaling to other cells are important for a cell to function properly. Responsible for those tasks...
Researchers at the University of New Hampshire have captured a difficult-to-view singular event involving "magnetic reconnection"--the process by which sparse particles and energy around Earth collide producing a quick but mighty explosion--in the Earth's magnetotail, the magnetic environment that trails behind the planet.
Magnetic reconnection has remained a bit of a mystery to scientists. They know it exists and have documented the effects that the energy explosions can...
Biochips have been developed at TU Wien (Vienna), on which tissue can be produced and examined. This allows supplying the tissue with different substances in a very controlled way.
Cultivating human cells in the Petri dish is not a big challenge today. Producing artificial tissue, however, permeated by fine blood vessels, is a much more...
Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.
In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...
On Saturday, 10 November 2018, the research icebreaker Polarstern will leave its homeport of Bremerhaven, bound for Cape Town, South Africa.
19.11.2018 | Event News
09.11.2018 | Event News
06.11.2018 | Event News
20.11.2018 | Physics and Astronomy
20.11.2018 | Medical Engineering
20.11.2018 | Physics and Astronomy